<div id="readability-page-1"><div><p>IN AN interview with private-equity investor David Rubenstein, chief executive officer of Novartis Dr Vasant Narasimhan spoke about the potential and possibilities of pharmaceuticals in a fiercely competitive industry.</p><p>Rubenstein questioned Dr Narasimhan on whether constant drug patent expiry and the need to generate new portfolio of drugs is a good way to make a business. Dr Narasimhan acknowledged the “constant treadmill” and the value of a company’s replacement power, which requires strong research and development capabilities, as well as long-term thinking.</p><p>Few industries in the world are subject to such clockwork-style competitive advantage erosion, where businesses know the exact year in which generic drug sales will erode their revenues.</p></div></div>

诺华制药

<p>诺华制药首席执行官 Vasant Narasimhan 博士讨论了制药行业面临的挑战和潜力，强调了强大研发和长期思维的重要性。他承认药物专利到期的持续压力以及对新药组合的需求，突出了行业独特竞争优势的侵蚀</p>

新加坡的生物技术战略将从集体合作而非竞争中获益